| Literature DB >> 35630762 |
Yang Wang1, Weiliang Cui2,3, Guowei Pang1, Lewen Xiong1, Qingzhi Liu1, Lili Xu1,2, Huifen Li1, Yongqiang Lin2.
Abstract
Citri Reticulatae Pericarpium Viride (CRPV) is the processed product of Citrus reticulata Blanco. We systematically analyzed two CRPV types, Geqingpi (GQP) and Sihuaqingpi (SHQP), based on powder color, microscopic characteristics, and chemical composition. In addition, we characterized their constituents via ultra-high-performance liquid chromatography with hybrid quadrupole-orbitrap mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS). Both showed significant differences in their powder color and microscopic characteristics. Fourier-transform infrared (FT-IR) spectroscopic analysis results showed that the C=O peak absorption of carboxylic acids and their carbonyl esters in SHQP was higher than that of GQP, while the C-OH and C-H plane bending peaks of polysaccharides were lower than those of GQP. We analyzed these data via similarity analysis, PCA, and OPLS-DA. GQP and SHQP had large distinct differences. Based on the mass measurements for molecular and characteristic fragment ions, we identified 44 main constituents from CRPV, including different flavonoid glycosides and flavonoid aglycones in SHQP and GQP, respectively. We found luteolin-6-C-glucoside, orientin, rhoifolin, and pilloin solely in SHQP, and naringenin and hesperetin only in GQP. The peak area measurements showed GQP having a higher flavonoid glycoside (narirutin, hesperidin, etc.) content, whereas SHQP had a higher polymethoxyflavone (nobiletin, tangeretin, etc.) content. Since we holistically analyzed two CRPV types, the results can not only support future pharmacological research, but also provide a scientific basis for formulating more reasonable CRPV quality standards and guide its clinical potential as a precision medicine.Entities:
Keywords: Citri Reticulatae Pericarpium Viride; Citrus reticulata Blanco; FT-IR; Geqingpi; Sihuaqingpi; TCM; UHPLC-Q-Exactive Orbitrap-MS; flavonoid aglycones; flavonoid glycosides; polymethoxyflavones
Mesh:
Substances:
Year: 2022 PMID: 35630762 PMCID: PMC9148031 DOI: 10.3390/molecules27103285
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Powder color of CRPV: GQP (a) and SHQP (b).
The value of L*, a*, and b* of GQP and SHQP.
| Variable Name | Sample Name | |
|---|---|---|
| GQP (n = 12) | SHQP (n = 10) | |
| L* | 62.0 ± 3.9 | 72.9 ± 2.7 ▲▲ |
| a* | 6.0 ± 0.6 | 1.6 ± 1.3 ▲▲ |
| b* | 13.8 ± 1.7 | 19.1 ± 1.7 ▲▲ |
| E*ab | 63.8 ± 4.1 | 75.6 ± 2.5 ▲▲ |
▲▲p < 0.01, as compared with the GQP.
Figure 2Cell images of the microscopic features of CRPV: GQP (a) and SHQP (b).
Figure 3FT-IR of GQP and SHQP.
Location of the most relevant features of the FT-IR spectra of the CRPV.
| Name | Wavenumber Term (cm−1) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | |
| GQP | 3419 | 2919 | — | 1646 | 1609 | 1518 | 1445 | 1372 | 1302 | 1276 | 1243 | 1203 | 1181 | 1131 | 1095 | 1070 | 889 | 841 | 814 | 766 | 740 |
| SHQP | 3419 | 2919 | 1746 | 1639 | — | 1518 | 1445 | 1372 | — | 1274 | — | — | — | — | — | 1072 | — | — | 812 | 764 | — |
Figure 4The basic peak chromatograms of CRPV in the positive ion mode and negative ion mode: GQP in positive ion mode (a); GQP in negative ion mode (b); SHQP in positive ion mode (c); SHQP in negative ion mode (d).
Identification of the chemical compounds of CRPV by UHPLC-Q-Exactive Orbitrap-MS.
| Compound/Peak Number | Identification | Molecular Formula | Retention Time (min) | [M + H]+ ( | [M − H]−( | Fragment Ions in the Positive Ion Mode ( | Fragment Ions in the Negative Ion Mode ( | Belongs |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 3 | Luteolin-6,8-di-C-glucoside c | C27H30O16 | 6.12 | 611.15961 | ND | 557.12787 [M + H-OCH2CH3]+, | ND | G/S |
| 4 | Victern-2 (apigenin-6,8-di-C-glucoside) c | C27H30O15 | 7.21 | 595.16406 | 593.15009 | 457.11102 [M + H-C4H8O4-H2O]+ | ND | G/S |
| 5 | Chrysoeriol-6,8-C-glucoside c | C28H22O16 | 7.72 | 625.17480 | 623.16058 | 487.11911 [M + H-C4H8O4-H2O]+, 367.08112 [M + H-2C4H8O4-H2O]+ | 503.12042 [M − H-C4H8O4]−, 413.08749 [M − H-C4H8O4-C3H6O3]−, 383.07684 [M − H-2C4H8O4]− | G/S |
| 6 | Luteolin-6-C-glucoside c | C21H20O11 | 9.04 | 449.10727 | 447.09268 | 413.08545 [M + H-2H2O]+, 395.07538 [M + H-3H2O]+, 329.06519 [M + H-C4H8O4]+, 299.05475 [M + H-C8H6O3]+ | ND | S |
| 7 | Orientin c | C21H20O11 | 9.52 | 449.10687 | ND | 431.09659 [M + H-H2O]+, 413.08609 [M + H-2H2O]+, 383.07559, 353.06506, 329.06506, 311.05478, 299.05450 | ND | S |
|
| ||||||||
| 8 | Eriodictyol-7-O-rutinoside c | C27H32O15 | 10.83 | 597.17963 | 597.17963 | 289.07040, 355.08051, 195.02887, 153.01813 | ND | G/S |
| 10 | Rhoifolin c | C27H30O14 | 14.01 | 579.16992 | 577.147 | 433.11099 [M + H-Rha]+, 271.05981 [M + H-Glc-Rha]+, 153.01849, 85.02903 | 269.04529 [M − H-Glc-Rha]− | S |
| 14 | 3-Hydroxy-3-methyl-5-oxo-5-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-methoxy-4-(5,7,8-trihydroxy-6-methoxy-4-oxochromen-2-yl)phenoxy]oxan-2-yl]methoxy]pentanoic acid/2-(3-Methoxy-4-hydroxyphenyl)-3-[6-O-(3,5-dihydroxy-3-methyl-5-oxopentanoyl)-beta-D-glucopyranosyloxy]-5,7-dihydroxy-8-methoxy-4H-1-benzopyran-4-one c | C29H32O17 | 16.44 | 653.16907 | 651.15558 | 347.07596, 332.05252, 301.03387, 187.05991, 145.04945, 127.03915, 85.02909 | 286.04791, 151.00246 | G/S |
| 15 | Torminaloside c | C28H30O16 | 16.84 | 623.15985 | 621.64514 | 317.06540 | 315.06540 [M − H-144-162]−, 271.02466, 151.00233 | G/S |
|
| ||||||||
| 9 | Narirutin a,c | C27H32O14 | 13.51 | 581.18439 | 579.17035 | 273.07533 [M + H-Glc-Rha]+, 195.02816, 153.01816, 85.02905 | 271.06091 | G/S |
| 12 | Hesperidin a,c | C28H34O15 | 15.18 | 611.19501 | 609.18109 | 303.08820 [M + H-Glc-Rha]+, 263.05466, 219.02869, 111.04427, 85.02897 | 301.07141 | G/S |
| 16 | Didymin c | C28H34O14 | 21.57 | 595.20013 | 593.18616 | 287.09140, 153.0204 | 285.07639 | G/S |
| 20 | Melitidin c | C33H40O18 | 26.34 | 725.22607 | 723.21222 | 419.13303 | ND | G/S |
|
| ||||||||
| 11 | Homoeriodictyol c | C16H14O6 | 15.19 | 303.08502 | 301.07068 | 153.01822 [M + H-C9H10O2]+ | 286.04791 [M − H-CH3]−,151.00233 [M − H-C9H10O2]− | G/S |
| 17 | Isosakuranetin c | C16H14O5 | 21.57 | 287.09030 | 285.07590 | 153.01819 [M + H-C9H10O]+, 133.06485, 161.05966 | 243.06580 [M − H-C2H2O]−, 151.00258 [M − H-C9H10O]− | G/S |
| 19 | Naringenin c | C15H12O5 | 25.93 | 273.07462 | 271.06021 | 153.01817 [M + H-C8H8O]+, | 151.00258 [M − H-C8H8O]−, 119.04896 [M − H-C7H4O4]−, 107.01255 [M − H-C8H8O-CO2]− | G |
| 23 | Hesperetin c | C16H14O6 | 27.73 | 303.08527 | 301.07068 | 153.01822 [M + H-C9H10O2]+, 287.07544, 219.06482, 171.02875, 177.05461 | ND | G |
|
| ||||||||
| 13 | Pilloin c | C17H14O6 | 15.60 | 315.08542 | ND | 300.06253 [M + H-CH3]+, 285.03963 [M + H-2CH3]+, 136.01561 [M + H-CH3-C9H8O3]+ | ND | S |
| 21 | Monohydroxy-trimethoxyflavone c | C18H16O6 | 26.55 | 329.10101 | ND | 314.07339 [M + H-CH3]+, 299.05457 [M + H-2CH3]+, 268.07254, 181.01285, 153.01811 | ND | G/S |
| 22 | 7-Hydroxy-3,5,6,8-tetramethoxyflavone c | C19H18O7 | 26.59 | 359.11145 | ND | 344.08826 [M + H-CH3]+, 301.07016 [M + H-2CH3-CO]+, 298.08319 | ND | G/S |
| 24 | 7-Hydroxy-3′,4′,5,6,8-pentamethoxyflavone c | C20H20O8 | 29.10 | 389.12201 | ND | 374.09921 [M + H-CH3]+, 359.07571 [M + H-2CH3]+, 341.06537 [M + H-2CH3-H2O]+ | ND | G/S |
| 25 | Isosinensetin (3′,4′,5,7,8-Pentamethoxyflavone) c | C20H20O7 | 29.66 | 373.12717 | ND | 343.08087 [M + H-2CH3]+, 315.08609 [M + H-2CH3-CO]+ | ND | G/S |
| 26 | 3′-Hydroxy-4′,5,6,7,8-Pentramethoxyflavone c | C20H20O8 | 30.77 | 389.12219 | ND | 374.09912 [M + H-CH3]+, 359.07562 [M + H-2CH3]+ | ND | G/S |
| 27 | 3,4′,5,7-Tetrametho-xyflavone c | C19H18O6 | 31.86 | 343.11694 | ND | 327.08597 [M + H-CH4]+, 328.09256 [M + H-CH3]+, 299.09109 [M + H-CH4-CO]+, 163.03397 | ND | G/S |
| 28 | Monohydroxy-hexamethoxyflavone c | C21H22O9 | 32.74 | 419.13324 | ND | 404.10974 [M + H-CH3]+, 389.08646 [M + H-2CH3]+ | ND | G/S |
| 29 | 5-Hydroxy-3′,4′,7,8-tetramethoxyflavone c | C19H18O7 | 33.12 | 359.11148 | ND | 197.0105 [M + H-C10H10O2]+, | ND | G/S |
| 30 | Sinensetin (3′,4′,5,6,7-Pentrametho-xyflavone) c | C20H20O7 | 33.22 | 373.12723 | ND | 357.09563 [M + H-CH4]+, 343.08081 [M + H-2CH3]+ | ND | G/S |
| 31 | 4′,5,6,7-Tetramethoxyflavone | C19H18O6 | 33.43 | 343.11673 | ND | 328.09363 [M + H-CH3]+, 317.07031, 285.07556, 181.01324, 153.01805 | ND | G/S |
| 32 | 3′,4′,5,7,8-Pentamethoxyflavanone c | C20H22O7 | 34.47 | 375.14322 | ND | 211.05995 [M + H-C10H10O2]+, | ND | G/S |
| 35 | Nobiletin (3′,4′,5,6,7,8-hexamethoxyflavone) a,c | C21H22O8 | 36.90 | 403.13779 | ND | 373.09137 [M + H-2CH3]+, 355.08060 [M + H-3CH3]+, 327.08591, 312.0705, 301.07031, 211.02361, 183.02884 | ND | G/S |
| 36 | 4′,5,7,8-Teramethoxyflavone c | C19H18O6 | 37.23 | 343.11685 | ND | 313.07028 [M + H-2CH3]+, 327.08560 [M + H-CH4]+ | ND | G/S |
| 37 | Dihydroxy-tetramethoxyflavone c | C19H18O8 | 37.86 | 375.10706 | ND | 360.08340 [M + H-CH3]+, 345.06018 [M + H-2CH3]+, 327.04971 [M + H-2CH3-H2O]+ | ND | G/S |
| 39 | 3,5,6,7,8,3′,4′-Hexamethoxyflavone c | C22H24O9 | 39.14 | 433.14835 | ND | 418.12482 [M + H-CH3]+,403.10187 [M + H-2CH3]+, 385.09146 [M + H-2CH3-H2O]+, 345.05917 [M + H-4CH3-CO]+, 211.02190, 165.05423 | ND | G/S |
| 40 | Tangeretin (4′,5,6,7,8-Pentamethoxyflavone) a,c | C20H20O7 | 40.56 | 373.12738 | ND | 358.10428, 343.08102 [M + H-2CH3]+, 297.07553, 183.02886, 135.04411 | ND | G/S |
| 41 | Monohydroxy-tetramethoxyflavone c | C19H18O7 | 42.31 | 359.11206 | ND | 343.08096, 315.08582, 298.08322, 164.08301 | ND | G/S |
| 42 | 5-Hydroxy-6,7,8,3′,4′-Pentamethoxyflavone c | C20H20O8 | 43.91 | 389.12213 | ND | 374.09550, 359.07574 [M + H-2CH3]+, 341.06528, 215.01813, 197.0119 [M + H-C10H12O2-2CH3]+ | ND | G/S |
| 43 | Natsudaidain (3-hydroxy-3′,4′,5,6,7,8-Hexamethoxyflavone) c | C21H22O9 | 46.20 | 419.13290 | ND | 389.08630 [M + H-2CH3]+, 371.07581 [M + H-2CH3-H2O]+, 361.09167 | ND | G/S |
| 44 | Monohydroxy-tetramethoxyflavone c | C19H18O7 | 47.65 | 359.11179 | ND | 344.08826 [M + H-CH3]+, 329.06528 [M + H-2CH3]+, 197.00768 | ND | G/S |
|
| ||||||||
| 1 | Stachydrine c | C7H13NO2 | 1.30 | 144.10161 | ND | 102.05531, 84.08133, 58.06592 | ND | G/S |
| 2 | Synephrine a,c | C9H13NO2 | 1.84 | 168.10179 | ND | 135.06801 [M + H-H2O-CH3]+, 119.04944 [M + H-H2O-CH3NO2]+, 107.04957 [M + H-H2O-CH3-CO]+, 91.05482, 81.07052 | ND | G/S |
| 18 | CitrusinIII c | C36H53N7O9 | 23.97 | 728.39557 | ND | 700.40399 [M + H-CO]+, 587.31830, 474.23471 | ND | G/S |
|
| ||||||||
| 33 | Limonin c | C26H30O8 | 35.15 | 471.20053 | 469.18555 | 425.19559 [M + H-H2O]+, 367.19043 [M + H-CH2O2-2CH3-H2O]+, 161.05972 | ND | G/S |
| 38 | Nomilin c | C28H34O9 | 39.03 | 515.22668 | ND | 469.22083 [M + H-CH2O2]+, 411.21735 [M + H-CH2O2-2CH3-H2O]+, 161.05966 | ND | G/S |
|
| ||||||||
| 14 | 2-(carbamoylamino)ethyl-[5-(dimethylamino)pentyl]-methyl-propylazanium/diethyl-[[[2-methyl-3-[1-(methylamino)butan-2-ylamino]propanoyl]amino]methyl]azanium c | C14H33ON4 | 35.54 | 274.27328 | ND | 256.26324, 106.08664, 88.07628 | ND | G/S |
G: Geqingpi belongs to CRPV; S: Sihuaqingpi belongs to CRPV; a Confirmation in comparison with authentic standards.; b Glc = glucose moiety, Rha = rhamnose moiety, ND: Not detected; c Confirmation in comparison with literature.
Figure 5The structure of flavone.
Figure 6The structure of flavanone.
Figure 7The structures of Limonin and Nomilin.
Compounds with the flavone structure.
| Name | R1 | R2 | R3 | R4 | R5 | R6 | R7 |
|---|---|---|---|---|---|---|---|
| Luteolin-6,8-di-C-glucoside | H | OH | Glc | OH | Glc | OH | OH |
| Victern-2 (apigenin-6,8-di-C-glucoside) | H | OH | Glc | OH | Glc | H | OH |
| Chrysoeriol-6,8-C-glucoside | H | OH | Glc | OH | Glc | OCH3 | OH |
| Rhoifolin | H | OH | H | ONeo | H | H | OH |
| Isosinensetin (3′,4′,5,7,8-Pentamethoxyflavone) | OCH3 | H | OCH3 | OCH3 | OCH3 | OCH3 | OCH3 |
| Sinensetin (5,6,7,3′,4′-Pentramethoxyflavone) | OCH3 | OCH3 | OCH3 | H | OCH3 | OCH3 | OCH3 |
| Nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone) | OCH3 | OCH3 | OCH3 | OCH3 | OCH3 | OCH3 | OCH3 |
| Tangeretin (5,6,7,8,4′-Pentamethoxyflavone) | OCH3 | OCH3 | OCH3 | OCH3 | H | H | OCH3 |
| 3,5,6,7,8,3′,4′-Hexamethoxyflavone | H | OCH3 | OCH3 | OCH3 | OCH3 | OCH3 | OCH3 |
Glc = glucose, Neo = neohesperidoside.
Compounds with the flavanone structure.
| Name | R1 | R2 | R3 |
|---|---|---|---|
| Narirutin | ORut | H | OH |
| Hesperidin | ORut | OH | OCH3 |
| Homoeriodictyol | OH | OCH3 | OH |
| Isosakuranetin | OH | H | OCH3 |
| Didymin | ONeo | H | OCH3 |
| Naringenin | OH | H | OH |
| Hesperetin | OH | OH | OCH3 |
Rut = rutinoside, Neo = neohesperidoside.
Similarity analysis of GQP and SHQP.
| Sample | G1 | G2 | G3 | G4 | G5 | G6 | G7 | G8 | G9 | G10 | G11 | G12 | S13 | S14 | S15 | S16 | S17 | S18 | S19 | S20 | S21 | S22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G1 | 1.00 | |||||||||||||||||||||
| G2 | 1.00 | 1.00 | ||||||||||||||||||||
| G3 | 1.00 | 1.00 | 1.00 | |||||||||||||||||||
| G4 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||||||||||
| G5 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||||||||
| G6 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||||||||
| G7 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||||||
| G8 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||||||
| G9 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||||
| G10 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||||
| G11 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||
| G12 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||
| S13 | 0.66 | 0.66 | 0.65 | 0.65 | 0.65 | 0.66 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | |||||||||
| S14 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | ||||||||
| S15 | 0.66 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | |||||||
| S16 | 0.66 | 0.66 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| S17 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||
| S18 | 0.66 | 0.66 | 0.66 | 0.66 | 0.66 | 0.66 | 0.66 | 0.65 | 0.66 | 0.66 | 0.66 | 0.66 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| S19 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||
| S20 | 0.66 | 0.66 | 0.65 | 0.65 | 0.66 | 0.66 | 0.65 | 0.65 | 0.66 | 0.66 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||
| S21 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| S22 | 0.66 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Figure 8Score plot (a) and bi plot (b) of PCA model; score plot (c), variable importance in projection (d), and permutation test (e) of OPLS-DA model based on data of FT-IR.
Figure 9Appearance characteristics of GQP (a) and SHQP (b).